Picker International's booth at the Society of Nuclear Medicinemeeting highlighted the vendor's second generation of productintroductions stemming from the launch of its simultaneous transmission-emissionprotocol (STEP) photon attenuation correction
Picker International's booth at the Society of Nuclear Medicinemeeting highlighted the vendor's second generation of productintroductions stemming from the launch of its simultaneous transmission-emissionprotocol (STEP) photon attenuation correction technique two yearsago.
The Cleveland company will introduce Converge, an investigationalenhancement to STEP that further improves image quality by fine-tuningthe geometric point response of the camera, according to JoshGurewitz, marketing manager.
Converge addresses partial volume effect, a form of image degradationcaused by differences in the physical distance between variouspoints of the targeted anatomy and the camera, Gurewitz said.It works by enhancing the remaining scatter component and correctingfor the point-spread function of the collimator, he said.
Converge will be available as an upgrade to STEP on the triple-headPrism 3000XP and will be a standard feature on a modificationof STEP earmarked for use on the dual-head Prism 2000XP. Internationalsales of the dual-head product will begin this summer. Food andDrug Administration 510(k) clearance is pending in the U.S.
Picker will also show NeuroFlow, a new xenon-133 brain imagingpackage for the 3000XP (SCAN 4/24/96). The FDA-cleared product,which quantifies regional cerebral blood flow, was developed withthe assistance of Dr. Michael Devous, associate director of nuclearmedicine at the University of Texas Southwestern Medical Centerin Dallas.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.